Favourable West Nile vaccine results
Friday, 27 February, 2009
Early results from a Phase I safety and efficacy trial of a West Nile virus vaccine, being developed by Acuvax’s US affiliate Hawaii Biotech, are “stunning”, the company said.
The results will enable an easier roll-out for a dengue fever vaccine, Acuvax’s CEO Dr William Ardrey said in a statement.
Hawaii Biotech, a private company in which Acuvax has a substantial shareholding, is trialling its vaccine in 24 healthy volunteers to check safety and antibody development.
All volunteers showed the presence of neutralizing antibodies. The vaccine is based on a proprietary recombinant DNA technology platform, which is being used by Hawaii to develop a vaccine for dengue fever, as well as candidates for malaria, tick-borne encephalitis virus and flu.
The company will now begin trials in children, the elderly and immuno-compromised patients.
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
